Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
28 mars 2024 07h00 HE
|
Galera Therapeutics
MALVERN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have...
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
14 nov. 2023 07h00 HE
|
Galera Therapeutics
FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa., Nov. 14,...
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
31 oct. 2023 07h00 HE
|
Galera Therapeutics
FDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass futility analysis; Company will discontinue both GRECO trials Company reviewing potential...
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem
18 sept. 2023 07h00 HE
|
Galera Therapeutics
MALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
05 sept. 2023 07h00 HE
|
Galera Therapeutics
MALVERN, Pa., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
14 août 2023 07h00 HE
|
Galera Therapeutics
Company received Complete Response Letter from FDA for avasopasem and intends to request Type A meeting with FDA to discuss potential next steps Cash runway extended into Q2 2024 in connection with...
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese
09 août 2023 16h31 HE
|
Galera Therapeutics
The Company remains committed to its goal of bringing avasopasem to patients and intends to meet with FDA as soon as possible to discuss potential next steps Galera will take actions to extend its...
Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting
05 juin 2023 14h15 HE
|
Galera Therapeutics
As previously reported, avasopasem reduced cisplatin-related chronic kidney disease by 50% compared to placebo at one-year follow-up Additional data demonstrated improved preservation of kidney...
Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer
18 mai 2023 08h00 HE
|
Galera Therapeutics
MALVERN, Pa., May 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates
11 mai 2023 07h00 HE
|
Galera Therapeutics
Avasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target date of August 9, 2023 Company raised $30 million in gross proceeds from registered...